This company listing is no longer active
2VB Stock Overview
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Provention Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.60 |
| 52 Week High | US$22.78 |
| 52 Week Low | US$3.23 |
| Beta | 2.46 |
| 1 Month Change | -0.60% |
| 3 Month Change | 174.81% |
| 1 Year Change | 391.47% |
| 3 Year Change | 111.76% |
| 5 Year Change | n/a |
| Change since IPO | 495.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2VB | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -4.2% | -1.0% | -1.7% |
| 1Y | 391.5% | -30.1% | 1.4% |
Return vs Industry: 2VB exceeded the German Pharmaceuticals industry which returned -0.9% over the past year.
Return vs Market: 2VB exceeded the German Market which returned -3.3% over the past year.
Price Volatility
| 2VB volatility | |
|---|---|
| 2VB Average Weekly Movement | 65.7% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2VB's share price has been volatile over the past 3 months.
Volatility Over Time: 2VB's weekly volatility has increased from 34% to 66% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 174 | Ashleigh Palmer | www.proventionbio.com |
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Provention Bio, Inc. Fundamentals Summary
| 2VB fundamental statistics | |
|---|---|
| Market cap | €2.15b |
| Earnings (TTM) | -€103.03m |
| Revenue (TTM) | €11.70m |
183.6x
P/S Ratio-20.8x
P/E RatioIs 2VB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2VB income statement (TTM) | |
|---|---|
| Revenue | US$12.90m |
| Cost of Revenue | US$76.32m |
| Gross Profit | -US$63.42m |
| Other Expenses | US$50.14m |
| Earnings | -US$113.56m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.20 |
| Gross Margin | -491.83% |
| Net Profit Margin | -880.69% |
| Debt/Equity Ratio | 19.3% |
How did 2VB perform over the long term?
See historical performance and comparison